Lucinda Y. Quan - 04 Feb 2022 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Role
Executive Vice President, Chief Business Officer and General Counsel
Signature
/s/ Lucinda Y. Quan
Issuer symbol
ALGS
Transactions as of
04 Feb 2022
Net transactions value
$0
Form type
4
Filing time
08 Feb 2022, 15:07:58 UTC
Next filing
11 Jul 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALGS Stock Option (Right to Buy) Award $0 +105,000 $0.000000 105,000 04 Feb 2022 Common Stock 105,000 $3.06 Direct F1
transaction ALGS Stock Option (Right to Buy) Award $0 +26,250 $0.000000 26,250 04 Feb 2022 Common Stock 26,250 $3.06 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
F2 100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date.

Remarks:

Executive Vice President, Chief Business Officer and General Counsel